Fig. 1
Development and characterization of vemurafenib and/or cobimetinib-resistant melanoma cell lines. A Parental and resistant cell lines were treated with increasing concentrations of vemurafenib, cobimetinib and their combination (0.001–5 µg/mL) for 72 h and then evaluated for proliferation by MTT staining. The table summarizes IC50 values and the relative fold-change in resistant versus parental cell lines. B Protein expression and phosphorylation levels of parental and resistant cell lines determined by western blot analysis in basal condition. C Confocal images of parental and resistant cell lines showing different tubulin organization. Different colors are applied to improve visualization: nuclei (DAPI) are in blue and microtubules in green. Scale bar for 40X objective: 20 μm; for 63X: 10 μm; maximum projection of Z-stack sections. D Expression level of proteins involved in epithelial-mesenchymal transition was detected by Western blot